SecBot SecBot

BLLN

BillionToOne, Inc.
Nasdaq· Services-Medical Laboratories· Inc. DE· CIK 0002070849 Healthcare & Medical Devices
$111.46 +3.69 (+3.43%)
Oct 26 4:00 PM ET · prev $107.77
Market cap
$5.0B
Mid cap
Consensus
Buy
80% Buy or better · 15 analysts
Median target
$130.00
+17% · range $110.00–145.00
Next earnings
Nov 4
in 9 days · EPS est. $0.30
1 year
+2.3%
from $108.94 · Nov 6
30 days
−8.4%
from $121.72
52-week range
$64.03–149.97
−26% from high · low Mar 12
Avg volume 20D
522.3K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$11.6M
0 buyers · 4 sellers · since Sep 14
New fund stakes
4
Q2 2026 13F · 1 exit
Filing reports
28
analyzed by SecBot
SecBot read BEARISH 13 reports · 90 days
Balance 5 bearish · 1 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 6/13 ·Next Earnings date, Nov 4, 2026
Strongest BEARISH Three insiders at BillionToOne, including the CEO and CTO, sold a total of $1.59M in open-market sales over…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $11.6M.

  • InstitutionsBULLISH

    Q2 2026: 33 added (4 new), 5 trimmed or exited. Largest new: Millennium Management $51.0M, Fuller & Thaler Asset Management, $50.2M.

  • AnalystsBULLISH

    12 of 15 rate it Buy or better. Median target $130.00 (+17%).

  • EstimatesRISING

    Current-quarter EPS estimate $0.245 → $0.300 over 90 days. 0 up, 1 down in 30 days.

  • TrendRANGE

    9% above its 50-day average.

Who's buying

13F· Q2 2026
4
new positions
1
exit
$129.0M
in new stakes
FundMoveSharesValue
PRICE T ROWE ASSOCIATES INC /MD/ADD1,010,322$121.2M
BAILLIE GIFFORD & COTRIM901,420$108.2M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED840,970$100.9M
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED799,468$95.9M
WASATCH ADVISORS LPADD518,084$62.2M
MILLENNIUM MANAGEMENT LLCNEW425,032$51.0M
FULLER & THALER ASSET MANAGEMENT, INC.NEW418,565$50.2M
UBS Group AGDOUBLED344,287$41.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 80% rate it Buy or better
Strong Buy6Buy6Hold3Sell0Strong Sell0
12-month targets · 7 analysts

Price is inside the target range. Median implies +17%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 1, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Sep 2, 2026Canaccord Genuity
INITIATE
INITIATEBuy
Aug 6, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 6, 2026BTIG
MAINTAIN
MAINTAINBuy
Jun 29, 2026Guggenheim
INITIATE
INITIATEBuy
May 13, 2026Guggenheim
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$11.6M
sold · 4 insiders
DateInsiderTypeValue
Oct 15, 2026
Atay Oguzhan
Chairman and CEO
EXERCISE$14.4K
Oct 15, 2026
Atay Oguzhan
Chairman and CEO
SELL$88.6K
Oct 15, 2026
Atay Oguzhan
Chairman and CEO
SELL$185.8K
Oct 15, 2026
Atay Oguzhan
Chairman and CEO
SELL$128.4K
Oct 15, 2026
Atay Oguzhan
Chairman and CEO
SELL$99.8K
Oct 15, 2026
Atay Oguzhan
Chairman and CEO
SELL$13.7K
Oct 14, 2026
Atay Oguzhan
Chairman and CEO
EXERCISE$8.9K
Oct 14, 2026
Atay Oguzhan
Chairman and CEO
SELL$303.1K

Earnings setup

Estimates
Nov 4
reports in 9 days
$0.30
EPS estimate, this quarter
+22%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.30$0.25–$0.35+22.4%$116.3M
Next Q🔒 Fresh data, subscribers only
Current FY$1.50$1.39–$1.60+71.8%$455.6M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Insider
Atay Oguzhan acquired via exercise 5,150 shares
Chairman and CEO @ $2.80 ($14.4K)
Oct 15, 2026 Insider
Atay Oguzhan sold 900 shares
Chairman and CEO @ $98.43 ($88.6K)
Oct 15, 2026 Insider
Atay Oguzhan sold 1,861 shares
Chairman and CEO @ $99.84 ($185.8K)
Sep 30, 2026 SEC
Three insiders at BillionToOne, including the CEO and CTO, sold a total of $1.59M in open-market sales over a one-week…
CLUSTER — Impact 5/10
Sep 28, 2026 SEC
Three insiders at BillionToOne, Inc. (BLLN) sold a total of $1.23M in stock over a one-week window, including the CTO…
CLUSTER — Impact 5/10
Sep 23, 2026 SEC
A cluster of insider sales at BillionToOne, Inc. (BLLN) totaling $1.09M over a 7-day window, led by Chairman/CEO…
CLUSTER — Impact 4/10
Sep 2, 2026 Other
BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generati
Jun 30, 2026 Inst.
PRICE T ROWE ASSOCIATES — ADD
1,010,322 shares ($121.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
BLLN Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Sep 2, 2026
Press release
BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission…
Aug 31, 2026
Short interest
Short Interest: BLLN up 20% to 2.3M shares
Settlement 2026-08-31 | Days to cover: 4.17 | ≈4.98% of shares outstanding (est.)
Aug 18, 2026
Press release
Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions
Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes…
Aug 5, 2026
Earnings date
BLLN Q2 2026 Earnings Scheduled — 2026-08-05
Jul 31, 2026
Short interest
Short Interest: BLLN down 20% to 1.9M shares
Settlement 2026-07-31 | Days to cover: 3.38 | ≈4.07% of shares outstanding (est.)

SecBot reports

28 filings · 1 press release · 3 bullish · 5 bearish · 20 neutral
All BLLN filing & press-release reports (29)